A systematic review of population pharmacokinetic analyses of digoxin in the paediatric population

• Published in: British journal of clinical pharmacology Vol. 86; no. 7; pp. 1267 - 1280
• Main Authors: Abdel Jalil, Mariam H., Abdullah, Noura, Alsous, Mervat M., Saleh, Mohammad, Abu‐Hammour, Khawla
• Format: Journal Article
• Language: English
• Published: England John Wiley and Sons Inc 01-07-2020
• Subjects: children; clearance; covariates; dose; heart failure; NONMEN; Review; trough; variability; heart failure; dose; children; covariates; clearance; trough; variability; NONMEN
• ISSN: 0306-5251; 1365-2125
• DOI: 10.1111/bcp.14272

This is a PROSPERO registered systematic review (CRD42018105207), conducted to summarize the available knowledge regarding the population pharmacokinetics of digoxin in paediatrics and to identify the sources of variability in its disposition. PubMed, ISI Web of Science, SCOPUS and Science Direct databases were searched from inception to January 2019. All paediatric population pharmacokinetic studies of digoxin that utilized the nonlinear mixed‐effect modelling approach were incorporated in this review, and data were synthesized descriptively. After application of the inclusion–exclusion criteria 8 studies were included. Most studies described digoxin pharmacokinetics as a 1‐compartment model with only 1 study describing its pharmacokinetics as 2‐compartments. Age was an important predictor of clearance in studies involving neonates or infants, other predictors of clearance were weight, height, serum creatinine, coadministration of spironolactone and presence of congestive heart failure. Congestive heart failure was also associated with an increased volume of distribution in 1 study. The estimated value of apparent clearance in a typical individual standardized by mean weight ranged between 0.24 and 0.56 L/h/kg, the interindividual variability in clearance ranged between 7.0 and 35.1%. Half of the studies evaluated the performance of their developed models via external evaluation. In conclusion, substantial predictors of digoxin pharmacokinetics in the paediatric population in addition to model characteristics and evaluation techniques are presented. For clinicians, clearance could be predicted using age especially in neonates or infants, weight, height, serum creatinine, coadministration of medications and disease status. For future researchers, designing pharmacokinetic studies that allow 2‐compartment modelling and linking pharmacokinetics with pharmacodynamics is recommended.